Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Saved in:
| Title: | Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario? |
|---|---|
| Authors: | Cerbone L; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), National Cancer Institute Regina Elena, Rome, Italy., Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy., Calabrò F; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), National Cancer Institute Regina Elena, Rome, Italy., Taha T; The Royal Marsden National Health Service (NHS) Foundation Trust, The Institute of Cancer Research, London, United Kingdom., Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Binz K; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Kansas City, KS, United States., Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Pirstuk A; Department of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia., Fiala O; Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czechia.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia., Molina-Cerrillo J; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Alonso-Gordoa T; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Rizzo A; S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori 'Giovanni Paolo II,', Bari, Italy., Pichler R; Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria., Myint ZW; Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States., Poprach A; Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czechia., Facchini G; Oncology Operative Unit, Santa Maria delle Grazie Hospital, Azienda Sanitaria Locale (ASL) NA2 NORD, P, ozzuoli, Napoli, Italy., Bohuslav M; Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czechia., Studentova H; Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czechia., Morelli F; Medical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo della Sofferenza, Foggia, Italy., Buchler T; Department of Oncology, Charles University and University Hospital Motol, Prague, Czechia., Mennitto A; Department of Medical Oncology, Azienda Ospedaliera Universitaria 'Maggiore Della Carità,', Novara, Italy., Tural D; Department of Medical Oncology, Koc University Medical Faculty, Istanbul, Türkiye., Formisano L; Department of Medicine and Surgery, Federico II University, Naples, Italy., Orejana I; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Catalano M; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Monteiro FSM; Oncology and Hematology Department, Hospital Sírio Libanês, Brasília, Brazil.; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Soares A; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.; Oncology Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil., Gupta S; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States., Massari F; Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Santoni M; Medical Oncology Unit, Macerata Hospital, Macerata, Italy. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Feb 24; Vol. 17, pp. 1667155. Date of Electronic Publication: 2026 Feb 24 (Print Publication: 2026). |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1667155 |
